Filing Flows › Inhibrx Biosciences (INBX) › Q2 2025
Inhibrx Biosciences (INBX) Q2 2025 earnings results (second quarter 2025)
10-Q filed Aug 13, 2025
Inhibrx Biosciences (INBX) reported revenue of $1.3M for the second quarter 2025 (Q2 2025), up 13-fold from a year earlier.
Inhibrx Biosciences, Q2 2025: revenue $1.3M (13× year over year), net loss $28.7M, operating cash flow −$30.0M. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.3M | — | 13× |
| Operating profit | −$27.4M | — | — |
| Net earnings | −$28.7M | — | — |
| Operating cash flow | −$30.0M | — | — |
What changed
Revenue was $1.3M in Q2 2025, up 1200% year over year.
Operating costs exceeded revenue by $27.4M, an operating margin of -2106.8%. Total costs fell 82% while revenue rose 1200%. The quarter ended with a net loss of $28.7M.
Operating cash flow was −$30.0M. Non-cash charges added back $662K of depreciation and amortization and $2.8M of share-based compensation. Working capital and other items used $4.7M.
Questions
What was Inhibrx Biosciences' revenue in the second quarter 2025?
Inhibrx Biosciences (INBX) reported revenue of $1.3M for the second quarter 2025 (Q2 2025), up 13-fold from a year earlier.